



COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment

Christophe Masset, Claire Garandeau, Aurélie Houzet, Delphine Kervella, Simon Ville, Diego Cantarovich, Alice Leclech, Claire Leman, Raphael Gaisne, Cécile Guillot-Gueguen, et al.

► To cite this version:

Christophe Masset, Claire Garandeau, Aurélie Houzet, Delphine Kervella, Simon Ville, et al.. COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment. *Kidney International Reports*, 2022, Online ahead of print. 10.1016/j.ekir.2022.10.002 . inserm-03891950

HAL Id: inserm-03891950

<https://inserm.hal.science/inserm-03891950>

Submitted on 9 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

COVID-19 Severity in Kidney Transplant Recipients According to Their Postvaccination Serological Assessment

Christophe Masset^{1,2}, Claire Garandeau¹, Aurélie Houzet¹, Delphine Kervella^{1,2}, Simon Ville^{1,2}, Diego Cantarovich¹, Alice Leclech¹, Claire Leman¹, Raphael Gaisne¹, Cécile Guillot-Gueguen¹, Océane Salomon¹, Clarisse Kerleau^{1,2}, Magali Giral^{1,2}, Jacques Dantal^{1,2} and Gilles Blancho^{1,2} and the Nantes DIVAT Consortium³

¹Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; and ²Center for Research in Transplantation and Translational Immunology, Nantes Université, INSERM, UMR 1064, Nantes, France

Correspondence: Christophe Masset, 30 bd Jean Monnet, 44093 Nantes Cedex 01, France. E-mail: christophe.masset@chu-nantes.fr

³Members of the Nantes DIVAT Consortium are listed in the Appendix

Received 20 September 2022; accepted 3 October 2022

Kidney Int Rep (2022) ■, ■-■; <https://doi.org/10.1016/j.ekir.2022.10.002>

KEYWORDS: Covid-19; kidney transplant recipient; mRNA vaccine

© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

INTRODUCTION

Susceptibility of kidney transplant recipients (KTRs) to COVID-19 has been acutely apparent because of their increased risk of developing severe pneumonia¹ and also, due to their lower vaccination response, conducing the transplant community to perform vaccine booster injections. Despite this, about 30% to 35% of patients remained seronegative after the third injection.^{2,3} Multiple reports highlighted the possibility of COVID-19 outbreak despite vaccination among KTRs,⁴ and the threshold of 264 BAU/ml antispikes IgG has been initially determined to correlate with a protective neutralizing activity against symptomatic COVID-19 by the Alpha variant of concern (VOC).⁵ With the ongoing Omicron pandemic, many SARS-CoV-2 infections occur despite efficient vaccination due to the immune escape of this VOC.⁶ However, there is no current assessment of how COVID-19 severity relates to the postvaccination serological status of KTRs.

We investigated the outcomes of SARS-CoV-2 infection in KTRs depending on their vaccination status, their preinfection IgG antispikes titer, administration of prophylactic monoclonal antibody and the VOC involved (Omicron or others).

RESULTS

Description of the Cohort

Among the 352 patients followed-up in our institution who contracted COVID-19, 306 KTRs were retained in

the final analysis as follows: 141 were not vaccinated (NO VAC), 45 were vaccinated without humoral response (SERO NEG), 44 were vaccinated with a weak humoral response (LOW POS), and 76 were vaccinated with a strong humoral response (HIGH POS) (Supplementary Figure S1). Complete methods of inclusion criterion, antibodies assays and groups definitions are described in the Supplementary Methods section. Specific treatments during COVID-19 and immunosuppression management among groups are summarized in Supplementary Table S1. The complete comparison between the groups' characteristics is described in Table 1 and Supplementary Table S2.

Humoral Responses After SARS-CoV-2 Vaccination

Of the KTRs, 72.8% developed a humoral response after vaccination. Almost all patients received an mRNA vaccine (1.8% received a heterologous vaccination). The serological assessment was performed 80 days (mean time) after the last injection, and SARS-CoV-2 infection was revealed 98 days (mean time) after the serological assessment. In the SERO NEG group, all patients except 2 had an undetectable humoral response; 2 had a detectable humoral response, though it was <1 BAU/ml. In the LOW POS group, the average humoral response level was 98 BAU/ml. In the HIGH POS group, all patients had a BAU titer >250/ml (greater than the laboratory's threshold). In comparison, 477 KTRs who did not develop COVID-19 were

Table 1. Description of the studied cohort

Patient's characteristics	All (n = 306)			NO VAC (n = 141)			SERO NEG (n = 45)			LOW POS (n = 44)			HIGH POS (n = 76)			P-value
	NA	n	%	NA	n	%	NA	n	%	NA	n	%	NA	n	%	
Male recipient	0	177	57.8	0	95	67.3	0	19	42.2	0	22	50.0	0	41	53.9	0.0100
Transplant rank ≥ 2	0	54	17.6	0	22	15.6	0	9	20.0	0	10	22.7	0	13	17.1	0.7117
Kidney transplant alone	0	272	88.8	0	123	87.2	0	43	95.5	0	40	90.9	0	66	86.8	0.4041
Deceased donor	3	260	85.8	1	123	87.8	0	39	86.6	0	35	79.5	2	63	85.1	0.7808
Calcineurin inhibitor treatment	0	264	86.2	0	120	85.1	0	39	86.6	0	43	97.7	0	62	81.5	0.0818
Belatacept treatment	0	14	4.5	0	6	4.2	0	3	6.6	0	0	0	0	5	6.5	0.3487
mTOR inhibitor treatment	0	27	8.8	0	13	9.2	0	2	4.4	0	2	4.5	0	10	13.1	0.2752
Antimetabolite treatment	0	229	74.8	0	103	73.0	0	35	77.7	0	35	79.5	0	56	73.6	0.7970
Steroid treatment	0	123	40.2	0	54	38.3	0	20	44.4	0	23	52.2	0	26	34.2	0.2259
Diabetes history	0	79	25.9	0	38	23.1	0	12	26.6	0	12	27.2	0	14	18.6	0.5253
Hypertension history	0	264	86.8	0	115	82.1	0	41	91.1	0	42	95.4	0	66	88.0	0.0826
Cardiovascular history	0	111	36.3	0	54	38.3	0	18	40.0	0	15	34.1	0	24	31.5	0.7207
RAAS blockers (ACEi or ARB)	0	102	33.3	0	52	36.8	0	11	24.4	0	18	40.9	0	21	27.6	0.1996
Respiratory history	1	51	16.7	0	30	21.2	1	16	35.5	1	8	18.1	1	9	12.0	0.0174
Neoplasia history	0	43	14.0	0	22	15.6	0	7	15.5	0	8	18.1	0	6	7.8	0.3377
	NA	Mean	SD	NA	Mean	SD	NA	Mean	SD	NA	Mean	SD	NA	Mean	SD	P-value
Recipient age (yr)	0	54.8	14.6	0	55.2	15.2	0	57.7	15.1	0	56.2	15.5	0	51.5	13.6	0.6474
Recipient BMI (kg.m ²)	15	25.0	5.0	5	25.5	5.0	4	25.5	5.5	1	25.0	5.2	5	23.9	4.4	0.1490
Time from transplantation (yr)	0	8.2	7.8	0	8.7	7.9	0	5.8	6.3	0	6.5	6.2	0	9.7	8.9	0.0511
Baseline sera creatinemia ($\mu\text{mol/l}$)	7	144.4	70.6	6	145.0	73.1	0	161.0	91.6	0	147.9	63.6	1	131.3	52.3	0.1390

ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; HIGH POS, strong humoral response; LOW POS, weak humoral response; SERO NEG, vaccinated without humoral response; RAAS, renin angiotensin aldosterone system.

vaccinated (3 doses) with available serological follow-up in our center. The overall seroconversion rate was 66.4%: 165 patients (33.5%) would be considered as SERO NEG, 125 as LOW POS (26.3%) and 192 as HIGH POS (40.2%) (Figure 1a–c).

COVID-19 Severity Depending on the Serological Status

Of the 306 included patients, 65 (21.2%) were hospitalized because of COVID-19: 48 in the NO VAC group (34.0% of the group); 10 in the SERO NEG group (22.2% of the group), 4 in the LOW POS group (9.1% of the group) and 3 in the HIGH POS group (3.9% of the group) (Figure 1d). These differences were significant between NO VAC and LOW POS ($P = 0.0020$), NO VAC and HIGH POS ($P < 0.0001$), SERO NEG and HIGH POS ($P = 0.0006$) and a trend between SERO NEG and LOW POS ($P = 0.0636$), Supplementary Table S3. Concerning intensive care unit admissions, they were significantly more frequent in the NO VAC group compared to the LOW POS group ($P = 0.0175$) and to the HIGH POS group ($P = 0.0018$), but also in the SERO NEG group compared to the LOW POS group ($P = 0.0237$) and to the HIGH POS group ($P = 0.0030$) (Figure 1e). Finally, patient death was more frequent in the NO VAC group compared to the HIGH POS group ($P = 0.0183$) (Figure 1f). The main symptoms and complications linked to SARS-CoV-2 infection are reported in Figure 1g. Mainly, patients vaccinated from the LOW POS and HIGH POS groups had a lower

occurrence of dyspnea, anosmia, hypoxemia, and acute kidney injury.

Among the 45 patients in the SERO NEG group, 15 received MoAb prophylaxis, which seemed to lower the probability of hospitalization (Supplementary Figure S2a–c).

Covid-19 Severity and the Variant Of Concern

A total of 166 patients presented a COVID-19 with a non-Omicron VOC and 140 patients were infected with the Omicron VOC (Supplementary Table S4–S7). Among patients with non-Omicron VOC, those from the HIGH POS group seemed to have a lower occurrence of severe COVID-19 forms (Supplementary Figure S3–S4). Among patients with Omicron, hospitalization and intensive care unit admission were higher in the SERO NEG group compared to the LOW POS and HIGH POS group ($P = 0.0529$ and $P = 0.0075$, respectively). Of note, the 9 patients from the NO VAC group were younger (49 years old vs. 57 years old) and with a lower body mass index (21.7 vs. 25.6) than patients from the SERO NEG group.

DISCUSSION

The results of our study confirm the significant benefit of SARS-CoV-2 vaccination in KTRs, leading to a lower rate of COVID-19 related hospitalizations, intensive care unit admissions and death. We demonstrated that a postvaccine humoral response, either high or low, drastically reduces occurrence of severe COVID-19 and




Figure 1. (a) Humoral response following SARS-CoV-2 vaccination in included COVID-19 patients from the 3 defined groups expressed by IgG antispikes (BAU/ml). (b) Humoral response following SARS-CoV-2 vaccination in a cohort control of vaccinated patients (3 doses) without COVID-19 infection expressed by IgG antispikes (BAU/ml). (c) Repartition of the patients depending on their postvaccination humoral response in the COVID-19 studied cohort and in the non-COVID-19 control cohort. (d) Survival without hospitalization depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (e) Survival without intensive care unit hospitalization depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (f) Survival without death depending on the vaccination status and the postvaccination serological assessment in the studied cohort. (g) Symptoms and major complications following COVID-19 depending on the vaccination status and the postvaccination serological assessment. (h) Representation of monthly new cases of COVID-19 in our center with the presumed different variants of concern based on the local epidemiology. (i) Representation of monthly new COVID-19 hospitalizations in our center with the presumed different variants of concern based on the local epidemiology. *represents a significant difference between NO VAC and LOW POS groups; §represents a significant difference between NO VAC and HIGH POS groups; ‡represents a significant difference between SERO NEG and LOW POS groups; †represents a significant difference between SERO NEG and HIGH POS groups; one symbol refers to a P-value < 0.05; 2 symbols to a P-value < 0.01 and 3 symbols to a P-value < 0.001. HIGH POS, strong humoral response; LOW POS, weak humoral response; SERO NEG, vaccinated without humoral response;

death among KTR patients. Our data supports the clinical practice of routinely assessing the humoral response in KTR patients after SARS-CoV-2 vaccination in order to determine patients remaining at high-risk of severe COVID-19 despite vaccination.

It is important to note that the difference between unvaccinated and vaccinated KTRs differs depending on the study period and thus on the different VOCs (unvaccinated patients were mostly infected with non-Omicron VOC, whereas vaccinated patients were mostly infected with Omicron). This is linked to the low proportion of KTRs who remain unvaccinated in 2022 (mainly patients without other risk-factors for severe COVID-19 which are refractory to vaccine themselves), and to the demonstrated neutralizing

activity of antispikes IgG induced by vaccination against non-Omicron VOCs, thus reducing outbreak of COVID-19 in this population.⁷ However, our observed outcomes in postvaccination seronegative patients suggest that Omicron remained in at-risk patients without humoral response. The 9 unvaccinated patients who were infected with Omicron did not develop severe COVID-19, but their low number, added to their few associated risk factors (they were notably younger with lower body mass index) prevented any conclusion to be drawn. In KTRs without a humoral response after vaccination, administration of prophylactic monoclonal antibody seemed to reduce the occurrence of severe COVID-19, and thus may be proposed for non-responders' patients.

Our study is limited by several biases. First, we conducted a monocentric retrospective study that lacks the strength to perform a robust adjusted statistical analysis. Second, because VOC screening was not routinely performed by all of the laboratories, we had to extrapolate them from the local epidemiology. Finally, because serological screening was performed, on average, several weeks before COVID-19, we assumed that the accuracy of these results may have been modified. Indeed, antispikes antibody titer slowly decreases over time,⁸ and this can explain why some KTRs with a high humoral response to the vaccine were infected with non-Omicron, and also, seronegative patients can convert several weeks later without any further injection.⁹

In conclusion, our study confirms the significant benefit of SARS-CoV-2 vaccination in KTRs and supports routine serological screening postvaccination in order to ensure the continued presence of antispikes IgG. Indeed, patients without a humoral response remained at-risk of severe forms of COVID-19, and thus may benefit from monoclonal antibody prophylaxis, which seems to attenuate COVID-19 severity.

APPENDIX

Members of the Nantes DIVAT Consortium *Données Informatisées et VALidées en Transplantation, DIVAT Cohort Collaborators (Medical Doctors, Surgeons, HLA Biologists)*

Gilles Blancho, Julien Branchereau, Diego Cantarovich, Anne Cesbron, Agnès Chapelet, Jacques Dantal, Anne Devis, Florent Delbos, Clément Deltombe, Lucile Figueres, Raphael Gaisne, Claire Garandeau, Magali Giral, Caroline Gourraud-Vercel, Maryvonne Hourmant, Christine Kandel-Aznar, Georges Karam, Clarisse Kerleau, Delphine Kervella, Claire Leman, Alice Leclech, Christophe Masset, Aurélie Houzet-Meurette, Karine Renaudin, Simon Ville, Alexandre Walencik.

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENTS

The authors thank all medical staff that took care of patients during the current COVID-19 pandemic. We also thank the clinical research associates who participated in the data collection. The analysis and interpretation of the data are the responsibility of the authors.

AUTHOR CONTRIBUTIONS

All authors participated in recruitment, follow-up, and treatment of the transplanted patients. CM performed the

analysis and wrote the manuscript. GB supervised data analysis and critically revised the manuscript. All authors reviewed the manuscript and approved the final version.

SUPPLEMENTARY MATERIAL

[Supplementary File \(PDF\)](#)

Supplementary Methods.

Supplementary Data.

Figure S1. Flowchart of the study.

Figure S2. Survival without hospitalization for seronegative recipients depending on the prophylaxis by specific monoclonal antibodies.

Figure S3. Survival without hospitalization depending on the vaccination status and the postvaccination serological assessment among different variants of concern.

Figure S4. Symptoms and major complications depending on vaccination status and postvaccination serological assessment among different variants of concern.

Table S1. Management of immunosuppressive drugs and specific anti SARS-CoV-2 therapy among studied patients.

Table S2. Excluded patients versus all patients.

Table S3. Successive *P*-values comparing the different cohorts in studied outcomes.

Table S4. Description of the subcohort infected with presumed non-Omicron VOC.

Table S5. Description of the vaccinated patients infected with presumed non-Omicron VOC depending on their postvaccine humoral response.

Table S6. Description of the subcohort infected with presumed Omicron VOC.

Table S7. Description of the vaccinated patients infected with presumed Omicron VOC depending on their postvaccine humoral response.

REFERENCES

1. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants. *Kidney Int.* 2020;98:1549–1558. <https://doi.org/10.1016/j.kint.2020.08.005>
2. Masset C, Kerleau C, Garandeau C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. *Kidney Int.* 2021;100:1132–1135. <https://doi.org/10.1016/j.kint.2021.08.017>
3. Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. *JAMA.* 2021;326:1063–1065. <https://doi.org/10.1001/jama.2021.12339>
4. Caillard S, Chavarot N, Bertrand D, et al. Occurrence of severe COVID-19 in vaccinated transplant patients. *Kidney Int.* 2021;100:477–479. <https://doi.org/10.1016/j.kint.2021.05.011>
5. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27:2032–2040. <https://doi.org/10.1038/s41591-021-01540-1>
6. Al Jurdi A, Gassen RB, Borges TJ, et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose

- of mRNA vaccine in kidney transplant recipients. *Kidney Int.* 2022;101:1282–1286. <https://doi.org/10.1016/j.kint.2022.04.009>
7. Mazuecos A, et al. Breakthrough infections following mRNA SARS-CoV-2 vaccination in kidney transplant recipients. *Transplantation.* 2022;106(7):1430–1439. <https://doi.org/10.1097/TP.0000000000004119>
8. Bertrand D, Lemée V, Laurent C, et al. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. *Am J Transplant.* 2022;22:1498–1500. <https://doi.org/10.1111/ajt.16954>
9. Boyarsky BJ, Chiang TP, Teles AT, et al. Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients. *Transplantation.* 2021; 105(10):e137–e138. <https://doi.org/10.1097/TP.00000000000003863>